Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | CD274 | Q9NZQ7 | 5/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL807590 | 0.91 | L3MBTL1 (0.42) | TACR1MEN1KMT2AL3MBTL1CD274 | |
| SCHEMBL15081966 | 0.90 | ALDH1A1 (0.41) | MEN1KMT2AL3MBTL1KDM4ETSHR | |
| SCHEMBL15081999 | 0.83 | MAPK1 (0.44) | TACR1SMN1; SMN2MAPK1 | |
| SCHEMBL807578 | 0.82 | ALDH1A1 (0.43) | MEN1KMT2AL3MBTL1CD274KDM4E | |
| SCHEMBL15081984 | 0.81 | MAPK1 (0.42) | TACR1ACHESMN1; SMN2MAPK1 | |
| SCHEMBL15081947 | 0.79 | TACR1 (0.51) | TACR1MEN1KMT2AL3MBTL1KDM4E | |
| SCHEMBL16133818 | 0.78 | TACR1 (0.49) | TACR1MEN1KMT2AL3MBTL1KDM4E | |
| SCHEMBL16133819 | 0.78 | TACR1 (0.49) | TACR1MEN1KMT2AL3MBTL1KDM4E | |
| SCHEMBL15081954 | 0.78 | TACR1 (0.49) | TACR1MEN1KMT2AL3MBTL1KDM4E | |
| SCHEMBL15084388 | 0.77 | CD274 (0.45) | MEN1KMT2AL3MBTL1CD274KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9242981-B2 | Fused pyrazole derivatives as novel ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-01-26 | — | — | US | disclosed |
| US-20130172341-A1 | FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS | MERCK SHARP & DOHME LLC | 2013-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172341-A1 | FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS | MAPK1, MAPK3, MAP3K1 | TACR1 3520/4885MEN1 2779/4885KMT2A 3379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.